vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $35.2M, roughly 1.9× Expensify, Inc.).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
EXFY vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $66.0M |
| Net Profit | — | $26.0M |
| Gross Margin | 49.2% | 98.3% |
| Operating Margin | -11.2% | 33.5% |
| Net Margin | — | 39.4% |
| Revenue YoY | -4.9% | — |
| Net Profit YoY | — | 134.0% |
| EPS (diluted) | $-0.07 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | — | ||
| Q3 25 | $35.1M | $66.0M | ||
| Q2 25 | $35.8M | $32.7M | ||
| Q1 25 | $36.1M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $35.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $26.0M | ||
| Q2 25 | $-8.8M | $-4.7M | ||
| Q1 25 | $-3.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.2M | — | ||
| Q2 24 | $-2.8M | — | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | 98.3% | ||
| Q2 25 | 51.9% | 97.9% | ||
| Q1 25 | 50.6% | — | ||
| Q4 24 | 51.0% | — | ||
| Q3 24 | 51.6% | — | ||
| Q2 24 | 56.9% | — | ||
| Q1 24 | 56.5% | — |
| Q4 25 | -11.2% | — | ||
| Q3 25 | -6.4% | 33.5% | ||
| Q2 25 | -28.9% | -20.0% | ||
| Q1 25 | -4.1% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | -5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | -6.6% | 39.4% | ||
| Q2 25 | -24.6% | -14.4% | ||
| Q1 25 | -8.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.2% | — | ||
| Q2 24 | -8.3% | — | ||
| Q1 24 | -11.3% | — |
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $-0.03 | $0.47 | ||
| Q2 25 | $-0.10 | $-0.09 | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $132.7M | $494.8M |
| Total Assets | $186.0M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | — | ||
| Q3 25 | $61.5M | $498.9M | ||
| Q2 25 | $60.5M | $286.8M | ||
| Q1 25 | $59.6M | — | ||
| Q4 24 | $48.8M | — | ||
| Q3 24 | $39.2M | — | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $49.3M | — |
| Q4 25 | $132.7M | — | ||
| Q3 25 | $135.7M | $494.8M | ||
| Q2 25 | $131.8M | $240.1M | ||
| Q1 25 | $134.7M | — | ||
| Q4 24 | $128.2M | — | ||
| Q3 24 | $119.9M | — | ||
| Q2 24 | $114.0M | — | ||
| Q1 24 | $106.5M | — |
| Q4 25 | $186.0M | — | ||
| Q3 25 | $186.8M | $599.9M | ||
| Q2 25 | $187.1M | $332.3M | ||
| Q1 25 | $189.2M | — | ||
| Q4 24 | $173.7M | — | ||
| Q3 24 | $176.2M | — | ||
| Q2 24 | $192.9M | — | ||
| Q1 24 | $184.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | — | ||
| Q3 25 | $4.2M | $43.5M | ||
| Q2 25 | $8.9M | $-12.6M | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $3.7M | — | ||
| Q2 24 | $9.3M | — | ||
| Q1 24 | $3.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
